Affimed (NASDAQ:AFMD) had its target price cut by research analysts at SunTrust Banks to $5.00 in a research note issued to investors on Thursday, The Fly reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks’ price objective points to a potential upside of 47.06% from the company’s current price. SunTrust Banks also issued estimates for Affimed’s Q3 2018 earnings at ($0.16) EPS, Q4 2018 earnings at ($0.15) EPS, FY2018 earnings at ($0.65) EPS, FY2019 earnings at ($0.39) EPS, FY2020 earnings at ($0.39) EPS, FY2021 earnings at ($0.31) EPS and FY2022 earnings at ($0.17) EPS.
A number of other equities research analysts have also recently commented on the company. Jefferies Financial Group upgraded Affimed from a “hold” rating to a “buy” rating and raised their target price for the company from $1.80 to $4.00 in a research report on Tuesday, August 28th. BidaskClub upgraded Affimed from a “strong sell” rating to a “sell” rating in a research report on Friday, August 31st. BMO Capital Markets dropped their target price on Affimed from $6.00 to $4.00 and set an “outperform” rating on the stock in a research report on Thursday, August 9th. ValuEngine upgraded Affimed from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 28th. Finally, Zacks Investment Research upgraded Affimed from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $4.81.
NASDAQ:AFMD opened at $3.40 on Thursday. Affimed has a 52 week low of $1.15 and a 52 week high of $7.35. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.33 and a current ratio of 5.36. The stock has a market cap of $271.40 million, a PE ratio of -4.36 and a beta of 3.57.
Large investors have recently bought and sold shares of the company. Stanley Laman Group Ltd. acquired a new stake in shares of Affimed during the 2nd quarter valued at about $100,000. Barclays PLC grew its position in shares of Affimed by 385.3% during the 1st quarter. Barclays PLC now owns 64,958 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 51,573 shares during the period. Canada Pension Plan Investment Board acquired a new stake in Affimed in the 2nd quarter worth about $165,000. Renaissance Technologies LLC boosted its holdings in Affimed by 38.8% in the 2nd quarter. Renaissance Technologies LLC now owns 177,510 shares of the biopharmaceutical company’s stock worth $293,000 after buying an additional 49,610 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in Affimed in the 1st quarter worth about $463,000. Hedge funds and other institutional investors own 40.63% of the company’s stock.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Read More: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.